The new perspectives of targeted therapy in acute myeloid leukemia
- PMID: 30141284
- DOI: 10.17219/acem/81610
The new perspectives of targeted therapy in acute myeloid leukemia
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease and the results of previous treatment with cytotoxic drugs have not been satisfactory. This situation has prompted investigations into novel approaches. The breakthrough in therapy brought by all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) and tyrosine kinase inhibitors in neoplasms with the Philadelphia chromosome has encouraged the search for other effective targeted therapies. Among the tested substances are higher molecular mass drugs such as antibodies and various small molecules: kinase inhibitors, cell pathway inhibitors and epigenetic modulators. So far, the U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate gemtuzumab ozogamycin (GO), the tyrosine kinase inhibitor midostaurin and the IDH2 inhibitor enasidenib. These studies have led to a better understanding of the mechanisms of leukemogenesis and may soon allow for differentiating treatments depending on baseline mutational complements. Some innovative drugs described in this article have strong therapeutic potential, but there is still a long way to go before actual success in targeted treatment.
Keywords: acute myeloid leukemia; immunotherapy; target therapy.
Similar articles
-
Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Curr Treat Options Oncol. 2017 Mar;18(3):17. doi: 10.1007/s11864-017-0456-2. Curr Treat Options Oncol. 2017. PMID: 28286924 Review.
-
[Incorporation of novel agents into the treatment for acute myeloid leukemia].Rinsho Ketsueki. 2018;59(10):1988-1996. doi: 10.11406/rinketsu.59.1988. Rinsho Ketsueki. 2018. PMID: 30305501 Review. Japanese.
-
Progress and predictions: AML in 2018.Best Pract Res Clin Haematol. 2018 Dec;31(4):337-340. doi: 10.1016/j.beha.2018.09.002. Epub 2018 Sep 20. Best Pract Res Clin Haematol. 2018. PMID: 30466743 Review.
-
Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia.Leukemia. 1996 Apr;10 Suppl 1:S12-5. Leukemia. 1996. PMID: 8618462 Review.
-
The Time Has Come for Targeted Therapies for AML: Lights and Shadows.Oncol Ther. 2020 Jun;8(1):13-32. doi: 10.1007/s40487-019-00108-x. Epub 2020 Jan 24. Oncol Ther. 2020. PMID: 32700072 Free PMC article. Review.
Cited by
-
The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers.Biomolecules. 2020 Jul 28;10(8):1112. doi: 10.3390/biom10081112. Biomolecules. 2020. PMID: 32731356 Free PMC article. Review.
-
Modulation of all-trans retinoic acid-induced MiRNA expression in neoplastic cell lines: a systematic review.BMC Cancer. 2019 Aug 30;19(1):866. doi: 10.1186/s12885-019-6081-7. BMC Cancer. 2019. PMID: 31470825 Free PMC article.
-
A bibliometric analysis of the research on hematological tumor microenvironment.Ann Transl Med. 2021 Aug;9(16):1337. doi: 10.21037/atm-21-3924. Ann Transl Med. 2021. PMID: 34532474 Free PMC article.
-
A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.Front Immunol. 2019 Jan 18;9:3153. doi: 10.3389/fimmu.2018.03153. eCollection 2018. Front Immunol. 2019. PMID: 30713535 Free PMC article.
-
Molecular Systems Architecture of Interactome in the Acute Myeloid Leukemia Microenvironment.Cancers (Basel). 2022 Feb 1;14(3):756. doi: 10.3390/cancers14030756. Cancers (Basel). 2022. PMID: 35159023 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
